Connect with us

BIOTECH

GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) Reports R&D Management Appointments

Published

on

GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) reported the engagement of Volker Knappertz, M.D. as its Chief Medical Officer. Reporting to company’s CEO Justin Gover, the new CMO will be based in the firm’s U.S. headquarters in California. In addition, the company reported that Professor Ben Whalley will be the new Head of Discovery Research, and he will be based in the U.K.

The details

The CEO of GW Pharmaceutical reported that he is thrilled to welcome Knappertz and Whalley to company in these major R&D roles. Knappertz has a remarkable record of new drug development and getting regulatory approvals which, with his extensive experience in neurology, makes him suited to lead company’s regulatory and clinical activities pertaining to Epidiolex® and their product pipeline. Additionally, Whalley’s leading position in the segment of Hemp science, especially pertaining to epilepsy, will be a major asset to company in the pursuit of their pipeline discovery programs.

Dr. Knappertz has clinical trial experience of over 25 years and pharmaceutical drug development experience of more than 17 years, holding leadership roles with responsibilities for managing global clinical study and medical affairs programs.

Recently, as the VP of clinical advancement for multiple sclerosis, oncology and biosimilar offerings at Teva Pharmaceuticals, Dr. Knappertz managed multiple regulatory filings and approvals in the United States, Europe, Japan and Canada. Prior to his role with Teva, Dr. Knappertz served in medical and clinical roles in CNS, biologics and CV at AstraZeneca and Bayer Pharmaceuticals.

Dr. Knappertz is a U.S. Board approved neurologist who obtained his residency training at Yale University, where he worked as chief resident and was trained at Wake Forest University. On his new role, Dr. Knappertz reported that he is extremely thrilled about the prospect to continue the work of offering regulatory approved Hemp-based pharmaceutical drugs to patients with unmet medical needs.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of MMJReporter.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure

BRANDS

DETAILS

SCORE

PRODUCT SITES

  • Certified Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49

9.8

30% OFF Today! “30 0FF”

  • All Natural
  • Made In U.S.A
  • Lab Tested
  • Price From $69

9.7

  • All Natural
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99

9.6

  • All Natural
  • Made In U.S.A
  • Oral Mist
  • Price From $39

9.5

BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49
SCORE

9.8

PRODUCT SITE
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Lab Tested
  • Price From $69
SCORE

9.7

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99
SCORE

9.6

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Oral Mist
  • Price From $39
SCORE

9.5

PRODUCT SITE VIEW PRODUCTS
Advertisement

Title

Uncategorized4 days ago

Top 15 Essential Oils + Health Benefits

Top 15 Essential Oils + Health Benefits Each and every essential oil contains compounds with unique healing and therapeutic benefits....

Uncategorized4 days ago

Using Hemp Oil in Cooking

Hemp oil has many advocates. The oil from hemp seeds is rich in omega-3 and omega-6 essential fatty acids. This makes...

Uncategorized1 week ago

Best Oil Producers of 2018

Millionaires are being made by the moment in the medical marijuana industry. Venture capital firms, private equity firms, and even...

MyDx Inc MyDx Inc
Health3 weeks ago

MyDx Inc. (OTCMKTS:MYDX) Initiates Clinical Trial of Cannabis Formula for The Treatment of Chronic Low Back Pain

San Diego, CA based MyDx Inc. (OTCMKTS:MYDX) has announced the controlled trial of the cannabis formula for the treatment of...

Business3 weeks ago

Fastfunds Financial Corporation (OTCMKTS:FFFC) Is All Set to Launch Affinity Connextions Program Targeting MMJ Industry

Fastfunds Financial Corporation (OTCMKTS:FFFC) has announced the completion of all necessary formalities to introduce an Affinity Connextions Program through a...

Innovative Industrial Properties Inc Innovative Industrial Properties Inc
Business3 weeks ago

Innovative Industrial Properties, Inc (NYSE:IIPR) Unveils Exercise Of Underwriter’s Option To Purchase Common Stock Shares

Innovative Industrial Properties, Inc (NYSE:IIPR) announced recently that it has obtained the exercise of the underwriter’s option to buy additional...

Business3 weeks ago

Next Generation Management Corporation (OTCMKTS:NGMC) Updates On New Medical Marijuana System in Oregon

Nextgen Holdings, a subsidiary of the Next Generation Management Corporation (OTCMKTS:NGMC) recently updated its stockholders with the ongoing Medical Marijuana...

INDUSTRIAL HEMP3 weeks ago

Weed Inc’s (OTCMKTS:BUDZ) Performance Is Getting Higher

Weed Inc (OTCMKTS:BUDZ) has for a long time been enjoying the momentous highs for the past few months. The company’s...

INDUSTRIAL HEMP3 weeks ago

Namaste Technologies Inc (OTCMKTS:NXTTF) Signs A Share Purchase Agreement With Cannbit Ltd

Namaste Technologies Inc (OTCMKTS:NXTTF) announced recently that it signed a non-binding Letter of Intent (LOI) with Cannabit Limited where the...

INDUSTRIAL HEMP3 weeks ago

MariMed Inc. (OTCMKTS:MRMD) Plans To Expand Its Cannabis Business

MeriMed Inc. (OTCMKTS:MRMD) announced its grand plans to expand business into the emerging cannabis industry. Furthermore, the company intends to...

Advertisement
Advertisement
Advertisement